BlackRock Institutional Trust’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

BlackRock Institutional Trust’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2.93M	Buy	380,570 +14,152	+4%	+$130K	﹤0.01%	2921
2016 Q3	$4.19M	Buy	366,418 +83,935	+30%	+$977K	﹤0.01%	2768
2016 Q2	$3.48M	Buy	282,483 +17,309	+7%	+$210K	﹤0.01%	2835
2016 Q1	$2.68M	Buy	265,174 +4,335	+2%	+$50.9K	﹤0.01%	2921
2015 Q4	$5.88M	Buy	260,839 +36,555	+16%	+$749K	﹤0.01%	2631
2015 Q3	$3.72M	Buy	224,284 +86,537	+63%	+$1.73M	﹤0.01%	2848
2015 Q2	$3.1M	Buy	137,747 +9,527	+7%	+$235K	﹤0.01%	2944
2015 Q1	$3.31M	Buy	128,220 +3,257	+3%	+$82.6K	﹤0.01%	2907
2014 Q4	$2.72M	Sell	124,963 -2,552	-2%	-$52.3K	﹤0.01%	2974
2014 Q3	$2.41M	Sell	127,515 -47,168	-27%	-$948K	﹤0.01%	2996
2014 Q2	$4.07M	Buy	174,683 +98,533	+129%	+$2.43M	﹤0.01%	2877
2014 Q1	$2.56M	Sell	76,150 -11,567	-13%	-$390K	﹤0.01%	3056
2013 Q4	$2.59M	Sell	87,717 -75,237	-46%	-$1.38M	﹤0.01%	3056
2013 Q3	$2.5M	Buy	+162,954	New	+$3.02M	﹤0.01%	3017

Other funds holding OMED

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

IHM

Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock Institutional Trust's OMED Position: Q4 2016 in Review

BlackRock Institutional Trust increased its OncoMed Pharmaceuticals, Inc. (OMED) stake by 3.9% in Q4 2016, buying an estimated $130K and bringing the position to 380,570 shares worth $2.93M. The position accounts for ﹤0.01% of the portfolio, ranked #2921.

BlackRock Institutional Trust first reported a position in OMED in Q3 2013 and has held it in 14 quarters since. The position peaked at $5.88M in Q4 2015. 86 funds tracked by Wall St. Rank hold OMED as of Q4 2016.

BlackRock Institutional Trust held 380,570 shares of OncoMed Pharmaceuticals, Inc. worth $2.93M as of Q4 2016.
BlackRock Institutional Trust bought 14,152 OncoMed Pharmaceuticals, Inc. shares in Q4 2016, an estimated $130K.
OncoMed Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #2921 holding.
BlackRock Institutional Trust first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and has held it in 14 quarters since.
BlackRock Institutional Trust's OncoMed Pharmaceuticals, Inc. position peaked at $5.88M in Q4 2015.
86 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.